AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Summary
- Both the healthcare sector companies have signed a contract on Thursday, 4 February.
- Under the agreement, Famar Health will be providing Active Biotech with clinical trial material.
Biotechnology company Active Biotech AB (Nasdaq Stockholm: ACTI) announced that it has entered into a manufacturing agreement with Paris-headquartered Famar Health Care Services Madrid SAU. According to the deal, clinical trial material of the newly developed eye-drop formulation of Laquinimod will be delivered by Famar, which provides pharmaceutical manufacturing and development services.
Active Biotech and Leukocare AG have developed a new formulation that will be studied for the treatment of uveitis, a non-infectious, serious, sight-threatening condition.
Copyright © 2020 Kalkine Media Pty Ltd.
Munich-based Leukocare is a biotechnology company which specializes in pharmaceutical formulation development. Ian Cooper, the chief executive officer at Famar, said the development service activity of Famar is the key element of the company’s strategy to enable development and expansion of its health care services and customers’ portfolio.
Helén Tuvesson, CEO of Active Biotech, said the deal will enable it to start the first clinical safety study with the newly developed eye-drop formulation of Laquinimod later this year.
Details of the agreement
The deal includes clinical trial material for dosing in clinical Phase I and II studies for the treatment of ophthalmic disorders. The R&D team of Famar will provide process development, scale-up, supply of material for pre-clinical local tolerance studies and clinical grade material to be used in the clinical studies.
With the launch of the project, Active Biotech aims to start a clinical safety study in second half of this year, and it also intends to commence with a proof-of-principle study with oral Laquinimod in uveitis patients in 2021.
Active Biotech AB, the biotechnology company, is engaged in the development of first-in-class immunomodulatory treatments for specialist oncology and immunology indications by applying its extensive knowledge base and portfolio of compounds.
At present, the company has three projects in its portfolio:
- Naptumomab, a targeted anti-cancer immunotherapy, which is in the Phase I/II clinical trial.
- Tasquinimod, treatment of multiple myeloma, which is in clinical Phase Ib/IIa.
- Laquinimod, a treatment of non-infectious uveitisa, which is advancing to phase 2.
Famar operates across six manufacturing sites and two R&D centres for pharmaceuticals and cosmetics in Greece, Italy and Spain. The company produces 1,700 unique product codes for pharmaceutical and cosmetic companies every year.
